Aisling Capital Management LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 13, 2025), Aisling Capital Management LP reported 13 stock positions worth $288.5 million. Its top holding was Bridgebio Pharma (BBIO) at 72.7% of the portfolio, followed by Verona Pharma (VRNA, 13.5%) and Syndax Pharmaceuticals (SNDX, 4.4%). Compared with Q4 2024, it sold out of 2, added to 1 and reduced 1. The biggest buy was Compass Pathways (CMPS, shares +24%) and the biggest sale Verona Pharma (VRNA, shares −45%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $288.5M (Q1 2025)
- SEC Filing
- 0001766721-25-000003 ↗ filed May 13, 2025
Holdings Value
Holdings 13 stocks · $288.5M
| BBIO Bridgebio Pharma Inc. | 72.72% | 6,068,125 | $209.8M | No change |
| VRNA Verona Pharma Ltd. | 13.54% | 615,352 | $39.1M | Reduce -44.8% |
| SNDX Syndax Pharmaceuticals Inc. | 4.36% | 1,025,000 | $12.6M | No change |
| BCAX Bicara Therapeutics Inc. | 2.57% | 568,919 | $7.4M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 2.37% | 1,472,331 | $6.8M | No change |
| NUVB Nuvation Bio Inc. | 1.55% | 2,541,009 | $4.5M | No change |
| CMPS Compass Pathways PLC | 1.19% | 1,198,418 | $3.4M | Add +24.3% |
| BMEA Biomea Fusion Inc. | 0.59% | 798,757 | $1.7M | No change |
| CALC Calcimedica Inc. | 0.35% | 521,114 | $995K | No change |
| ELEV Elevation Oncology Inc. | 0.25% | 2,834,910 | $735K | No change |
| ACRS Aclaris Therapeutics Inc. | 0.23% | 434,455 | $665K | No change |
| MRKR Marker Therapeutics Inc. | 0.14% | 325,370 | $400K | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.13% | 88,607 | $381K | No change |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
| CMPS Compass Pathways PLC | Add +24.3% | 1.19% | −0.11 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |